UK Markets close in 1 hr

Gain Therapeutics, Inc. (GANX)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
7.00-0.14 (-1.96%)
As of 10:12AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close7.14
Open7.10
Bid6.55 x 1400
Ask7.08 x 1800
Day's range7.00 - 7.10
52-week range6.50 - 17.93
Volume5,785
Avg. volume138,483
Market cap83.136M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est30.00
  • Globe Newswire

    Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer

    BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the appointment of Matthias Alder as Chief Operating Officer to advance the Company’s strategic and operational objectives, including the establishment of additional industry partnerships and the

  • Globe Newswire

    Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

    Conference Dates: September 27th-30thBETHESDA, Md., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Cantor Virtual Global Healthcare Conference and invites investors to part

  • Globe Newswire

    Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

    - Conference Dates: September 20th-23rd - BETHESDA, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and invit